SCHEMBL22802414

SCHEMBL22802414

COc1c(F)c(Cn2cccn2)cc(F)c1C#N

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 10/20 0.45
▸ KAT6A Q92794 10/20 0.45
▸ KAT6B Q8WYB5 7/20 0.45
▸ KAT5 Q92993 3/20 0.38
▸ KAT8 Q9H7Z6 3/20 0.38
▸ SCN9A Q15858 2/20 0.35
▸ PDE4B Q07343 2/20 0.35
▸ MAPT P10636 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29490395 1.00 KAT7 (0.45) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31432542 0.89 KAT7 (0.36) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31371951 0.88 KAT7 (0.36) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31432470 0.88 KAT7 (0.36) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31432516 0.88 KAT7 (0.36) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31432574 0.87 KAT7 (0.38) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31432519 0.86 KAT7 (0.37) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL25565517 0.81 BRD4 (0.39) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31371880 0.81 GAA (0.39) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL25214173 0.79 KAT7 (0.39) KAT7KAT6AKAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741389-A1 KAT6 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2026-05-13 — — EP disclosed
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 — — US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 — — EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 — — US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 — — EP disclosed
WO-2025036382-A1 SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海复宏汉霖生物医药有限公司 2025-02-20 — — WO disclosed
WO-2025007873-A1 KAT6 INHIBITOR 上海齐鲁制药研究中心有限公司 2025-01-09 — — WO disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 — — EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 — — EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 — — EP disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 — — US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 — — US disclosed
WO-2023088233-A1 LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-25 — — WO disclosed
US-11492346-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2022-11-08 — — US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 — — EP disclosed
CN-114364672-A Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2022-04-15 — — CN disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 — — US disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 — — WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR KAT7 1841/4885KAT6A 3700/4885KAT6B 2765/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR KAT7 1917/4885KAT6A 3783/4885KAT6B 2859/4885
US-11492346-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR KAT7 1841/4885KAT6A 3700/4885KAT6B 2765/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 KAT7 3/4885KAT6A 7/4885KAT6B 16/4885
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR KAT7 1841/4885KAT6A 3700/4885KAT6B 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback